FDA Converts to Full Approval Indication for Keytruda® (Pembrolizumab) for Certain Adult and Pediatric Patients with Advanced Microsatellite Instability-High (Msi-H) or Mismatch Repair Deficient (dMMR) Solid Tumors

0
251
Merck announced that the US FDA has granted full approval to KEYTRUDA for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.
[Merck]
Press Release